Small changes in calcium replacement therapy triggering hypercalcaemia and rising creatinine

Abstract

In this article, we present four cases of renal failure secondary to hypercalcaemia which were brought to the attention of our hospital's nephrology team. These happened in the setting of simple medication changes for hypoparathyroidism post-thyroid surgery. These cases have in common minor changes in preparations leading to significant adverse events. In two cases, excipient changes were the only changes identified in the patients' regimen. In all cases, cessation of the offending calcium preparation and treatment with IV rehydration led to a return to baseline creatinine levels. Communicating to patients the importance of consistency in how calcium and vitamin D supplements are taken is crucial in preventing adverse effects. Prescribers should be aware of excipient changes and that these are not always clinically insignificant.

Keywords

Hypercalcaemia acute kidney injury excipients sucralose post-thyroidectomy hypoparathyroidism

Get full access to this article

View all access options for this article.

References

Kellum

, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1–138.

Mehta

, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.

Felsenfeld

Levine

. Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol 2006; 1: 641–654.

Patel

Goldfarb

. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 2010; 21: 1440–1443.

Arroyo

Fenvues

Emmett

. The calcium-alkali syndrome. Baylor Univ Med Center Proc 2013; 26: 179–181.

Patel

Adeseun

Goldfarb

. Calcium-alkali syndrome in the modern era. Nutrients 2013; 5: 4880–4893.

Picolos

Lavis

Orlander

. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endrocinol 2005; 63: 566–576.

Electronic Medicines Compendium. Calcichew 500mg Chewable Tablets. Electronic Medicines Compendium, www.medicines.org.uk/emc/product/5232/smpc (accessed 15 April 2018).

Electronic Medicines Compendium. Calcichew Forte Chewable Tablets. Electronic Medicines Compendium, www.medicines.org.uk/emc/product/5230/smpc (accessed 8 April 2019).

10.

No author listed. What are excipients doing in medicinal products?. Drug Ther Bull 2009; 47: 81–84.

11.

Kumar

. Adverse effects of pharmaceutical excipients. Adverse Drug React Bull 2003; 222: 851–854.

12.

Schiffman

Other

. Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health Part B 2013; 16: 399–451.

13.

No author listed. Effects of sucralose on drug absorption and metabolism (The SweetMeds Study). Clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT03407079 (accessed 1 June 2019).

14.

European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product, www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003382.pdf (2007, accessed 9 September 2018).

Small changes in calcium replacement therapy triggering hypercalcaemia and rising creatinine – a case series

Abstract

Keywords

Get full access to this article

References